Glyphosate-cancer trials postponed while Bayer, plaintiffs negotiate potential $8-$12 billion settlement

| | December 9, 2019
s reutersmedia net
Credit: Reuters
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Germany’s Bayer has agreed with plaintiffs to postpone its next two U.S. lawsuits over the alleged cancer-causing effects of its glyphosate-based weed killers to allow more time for talks on a settlement.

The company, which is facing 42,700 U.S. plaintiffs, is widely expected to eventually buy itself out of the litigation, with analysts currently estimating the size of a future settlement at $8-$12 billion.

Read full, original article: Bayer reaches agreement to postpone more glyphosate lawsuits for settlement talks

Related article:  European commission plans to relicense glyphosate for 10 years according to leaked proposal
Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend